GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Medicenna Therapeutics Corp (TSX:MDNA) » Definitions » EV-to-FCF

Medicenna Therapeutics (TSX:MDNA) EV-to-FCF : -11.45 (As of May. 04, 2024)


View and export this data going back to 2015. Start your Free Trial

What is Medicenna Therapeutics EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Medicenna Therapeutics's Enterprise Value is C$156.96 Mil. Medicenna Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was C$-13.71 Mil. Therefore, Medicenna Therapeutics's EV-to-FCF for today is -11.45.

The historical rank and industry rank for Medicenna Therapeutics's EV-to-FCF or its related term are showing as below:

TSX:MDNA' s EV-to-FCF Range Over the Past 10 Years
Min: -11.45   Med: 0   Max: 0.43
Current: -11.45

During the past 9 years, the highest EV-to-FCF of Medicenna Therapeutics was 0.43. The lowest was -11.45. And the median was 0.00.

TSX:MDNA's EV-to-FCF is ranked worse than
100% of 392 companies
in the Biotechnology industry
Industry Median: 4.57 vs TSX:MDNA: -11.45

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-04), Medicenna Therapeutics's stock price is C$2.39. Medicenna Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was C$-0.220. Therefore, Medicenna Therapeutics's PE Ratio for today is At Loss.


Medicenna Therapeutics EV-to-FCF Historical Data

The historical data trend for Medicenna Therapeutics's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Medicenna Therapeutics EV-to-FCF Chart

Medicenna Therapeutics Annual Data
Trend Dec15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only -2.41 -24.16 -15.24 -3.02 -2.19

Medicenna Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.63 -2.19 -1.08 -0.16 -0.55

Competitive Comparison of Medicenna Therapeutics's EV-to-FCF

For the Biotechnology subindustry, Medicenna Therapeutics's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Medicenna Therapeutics's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Medicenna Therapeutics's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Medicenna Therapeutics's EV-to-FCF falls into.



Medicenna Therapeutics EV-to-FCF Calculation

Medicenna Therapeutics's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=156.963/-13.706
=-11.45

Medicenna Therapeutics's current Enterprise Value is C$156.96 Mil.
Medicenna Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-13.71 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Medicenna Therapeutics  (TSX:MDNA) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Medicenna Therapeutics's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=2.39/-0.220
=At Loss

Medicenna Therapeutics's share price for today is C$2.39.
Medicenna Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-0.220.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Medicenna Therapeutics EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Medicenna Therapeutics's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Medicenna Therapeutics (TSX:MDNA) Business Description

Traded in Other Exchanges
Address
2 Bloor Street W., 7th Floor, Toronto, ON, CAN, M4W 3E2
Medicenna Therapeutics Corp is a Canada-based immuno-oncology company. Its principal business activity is the development and commercialization of IL-2, IL-4, and IL13 Superkines and Empowered Superkines for the treatment of cancer and other diseases. Its pipeline candidates include MDNA55 for recurrent glioblastoma multiforme (rGBM), MDNA11 for Cancer immunotherapies, MDNA209 for Autoimmune Diseases, MDNA413 for Cancer immunotherapies, and MDNA132 for Solid Tumors, BiSKITs represents the novel platform comprised of Bifunctional SuperKine ImmunoTherapies.

Medicenna Therapeutics (TSX:MDNA) Headlines

No Headlines